Sign In
Buy CRIS
$0.500
-0.0025 (-0.498%)
At Close: Jun 03, 2026
Curis Reports Fourth Quarter and Year-End 2020 Financial Results
04:01pm, Tuesday, 16'th Mar 2021
LEXINGTON, Mass., March 16, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported
Curis Announces Abstract for CA-4948 Accepted for Presentation at the American Association for Cancer Research Annual Meeting
04:30pm, Wednesday, 10'th Mar 2021
LEXINGTON, Mass., March 10, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced
Curis: Differentiated IRAK4 Inhibitor To Drive Value Creation In The Near Term
02:00pm, Monday, 01'st Mar 2021
Shares have gained 20% year to date and risen by over 600% in the past 3 months.
Curis Inc.: Understanding CI-8993 And VISTA
09:16am, Wednesday, 27'th Jan 2021
Quick overview of Curis and stock price history. Review on the potential for therapies that target the immune system checkpoint regulator “VISTA” (V-domain immunoglobulin (Ig) suppressor of T cell
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
04:01pm, Friday, 08'th Jan 2021
LEXINGTON, Mass., Jan. 8, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced th
Curis Inc.: Understanding CA-4948 And IRAK-4 Inhibition
03:39pm, Wednesday, 23'rd Dec 2020
Overview of Curis, including key partnerships, balance sheet, and recent stock price. Review of Non-Hodgkin's Lymphoma, Myelodysplastic Syndromes and Acute Myeloid Leukemia. Patient need, current key
Small Cap Momentum Stories to Watch (NASDAQ: BLNK) (OTC US: MMEDF) (OTC US: CLKA) (NASDAQ: CRIS)
08:14am, Wednesday, 16'th Dec 2020
Small Cap Momentum Stories to Watch (NASDAQ: BLNK) (OTC US: MMEDF) (OTC US: CLKA) (NASDAQ: CRIS)
The Hits Keep Coming With Curis's Secondary Offering
09:53am, Wednesday, 09'th Dec 2020
Curis Inc. (NASDAQ: CRIS) shares are on the run again.
Curis Announces Pricing of Public Offering of Common Stock
09:29am, Wednesday, 09'th Dec 2020
LEXINGTON, Mass., Dec. 9, 2020 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced the
Curis Stock Price Increases 354.86%: Why It Happened
04:24pm, Tuesday, 08'th Dec 2020
The stock price of Curis, Inc. (NASDAQ: CRIS) increased by 354.86% as it went from a previous close of $1.44 to $6.55 per share today. This is why it happened.
Stitch Fix Helps Nasdaq Stretch Toward Records; Curis Erupts Higher
02:40pm, Tuesday, 08'th Dec 2020
Further gains for the top stock market came from big movers.
Curis Surges 330% On Early Stage Blood Cancer Data
11:17am, Tuesday, 08'th Dec 2020
Curis, Inc. (NASDAQ: CRIS) shares were skyrocketing Tuesday on above-average volume after the company announced updated Phase 1 data on its investigational asset CA-4948 in treating acute myeloid leu
This Curis Cancer Study Is a Big Hit
09:56am, Tuesday, 08'th Dec 2020
After Curis Inc. (NASDAQ: CRIS) announced preliminary data from its ongoing early-stage study in patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS), its shares abs
Curis stock more than triples on massive volume after upbeat leukemia treatment trial results
09:19am, Tuesday, 08'th Dec 2020
Shares of Curis Inc. more than tripled Tuesday, to lead all premarket gainers and with the most volume, after the biotechnology company announced positive preliminary data from a Phase 1 study of its
LEXINGTON, Mass., Dec. 7, 2020 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced up
